FDA Says Keryx (KERX) Promoted Investigational and Unapproved Drug on Co. Website
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
FDA says on June 30th it sent a letter to Keryx Biopharma (Nasdaq: KERX) alleging the company promoted its unapproved and investigational drug on the company's website.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Elroy Air wins $46M U.S. Army contract for cargo drone system
- Hinge Health signs $86M office lease in San Francisco
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
